BlackRock’s Oramed Pharmaceuticals ORMP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $313K | Buy |
92,192
+1,980
| +2% | +$6.72K | ﹤0.01% | 4638 |
|
|
2025
Q4 | $257K | Sell |
90,212
-19,521
| -18% | -$50.3K | ﹤0.01% | 4653 |
|
|
2025
Q3 | $290K | Buy |
109,733
+24,163
| +28% | +$53.4K | ﹤0.01% | 4601 |
|
|
2025
Q2 | $193K | Sell |
85,570
-6,754
| -7% | -$14.9K | ﹤0.01% | 4677 |
|
|
2025
Q1 | $198K | Sell |
92,324
-1,381
| -1% | -$3.19K | ﹤0.01% | 4604 |
|
|
2024
Q4 | $227K | Buy |
93,705
+1,696
| +2% | +$4.03K | ﹤0.01% | 4598 |
|
|
2024
Q3 | $225K | Buy |
92,009
+2,303
| +3% | +$5.62K | ﹤0.01% | 4506 |
|
|
2024
Q2 | $231K | Buy |
89,706
+411
| +0.5% | +$977 | ﹤0.01% | 4520 |
|
|
2024
Q1 | $261K | Buy |
89,295
+1,537
| +2% | +$4.3K | ﹤0.01% | 4533 |
|
|
2023
Q4 | $203K | Sell |
87,758
-1,040
| -1% | -$2.22K | ﹤0.01% | 4632 |
|
|
2023
Q3 | $232K | Sell |
88,798
-9,232
| -9% | -$29.1K | ﹤0.01% | 4637 |
|
|
2023
Q2 | $351K | Buy |
98,030
+8,359
| +9% | +$26.8K | ﹤0.01% | 4588 |
|
|
2023
Q1 | $195K | Sell |
89,671
-16,229
| -15% | -$51.6K | ﹤0.01% | 4783 |
|
|
2022
Q4 | $1.27M | Buy |
105,900
+3,701
| +4% | +$28.8K | ﹤0.01% | 4330 |
|
|
2022
Q3 | $662K | Sell |
102,199
-36,853
| -27% | -$298K | ﹤0.01% | 4632 |
|
|
2022
Q2 | $637K | Sell |
139,052
-1,691,114
| -92% | -$9.04M | ﹤0.01% | 4693 |
|
|
2022
Q1 | $15.8M | Buy |
1,830,166
+271,559
| +17% | +$2.78M | ﹤0.01% | 3319 |
|
|
2021
Q4 | $22.3M | Buy |
1,558,607
+125,059
| +9% | +$2.61M | ﹤0.01% | 3209 |
|
|
2021
Q3 | $31.5M | Buy |
1,433,548
+164,018
| +13% | +$2.79M | ﹤0.01% | 2973 |
|
|
2021
Q2 | $17M | Buy |
1,269,530
+1,190,970
| +1,516% | +$13.6M | ﹤0.01% | 3399 |
|
|
2021
Q1 | $798K | Buy |
78,560
+9,825
| +14% | +$80.6K | ﹤0.01% | 4544 |
|
|
2020
Q4 | $292K | Sell |
68,735
-20,266
| -23% | -$66K | ﹤0.01% | 4420 |
|
|
2020
Q3 | $232K | Buy |
89,001
+16,963
| +24% | +$59.1K | ﹤0.01% | 4384 |
|
|
2020
Q2 | $254K | Buy |
72,038
+26,042
| +57% | +$87.4K | ﹤0.01% | 4327 |
|
|
2020
Q1 | $140K | Sell |
45,996
-11,840
| -20% | -$51.9K | ﹤0.01% | 4291 |
|
|
2019
Q4 | $298K | Sell |
57,836
-13,793
| -19% | -$51.7K | ﹤0.01% | 4260 |
|
|
2019
Q3 | $228K | Sell |
71,629
-2,662
| -4% | -$8.87K | ﹤0.01% | 4313 |
|
|
2019
Q2 | $267K | Buy |
74,291
+2,423
| +3% | +$8.55K | ﹤0.01% | 4320 |
|
|
2019
Q1 | $261K | Buy |
71,868
+2,525
| +4% | +$8.35K | ﹤0.01% | 4206 |
|
|
2018
Q4 | $208K | Buy |
69,343
+40,114
| +137% | +$166K | ﹤0.01% | 4220 |
|
|
2018
Q3 | $142K | Buy |
29,229
+1,188
| +4% | +$6.17K | ﹤0.01% | 4391 |
|
|
2018
Q2 | $209K | Buy |
+28,041
| New | +$203K | ﹤0.01% | 4293 |
|
Other funds holding ORMP
BCM
AF
GIA
M
BFM
RG
BlackRock's ORMP Position: Q1 2026 in Review
BlackRock increased its Oramed Pharmaceuticals (ORMP) stake by 2.2% in Q1 2026, buying an estimated $6.72K and bringing the position to 92,192 shares worth $313K. The position accounts for ﹤0.01% of the portfolio, ranked #4638.
BlackRock first reported a position in ORMP in Q2 2018 and has held it in 32 quarters since. The position peaked at $31.5M in Q3 2021. 64 funds tracked by Wall St. Rank hold ORMP as of Q1 2026.
- BlackRock held 92,192 shares of Oramed Pharmaceuticals worth $313K as of Q1 2026.
- BlackRock bought 1,980 Oramed Pharmaceuticals shares in Q1 2026, an estimated $6.72K.
- Oramed Pharmaceuticals made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #4638 holding.
- BlackRock first reported a position in Oramed Pharmaceuticals in Q2 2018 and has held it in 32 quarters since.
- BlackRock's Oramed Pharmaceuticals position peaked at $31.5M in Q3 2021.
- 64 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2026.
Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.